Status:
COMPLETED
A Study of Participants in Australia Who Have Non-small Cell Lung Cancer Being Treated With Nivolumab
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Adult male or female (≥18 years of age) patients with NSCLC
- Treated with nivolumab on the Australian PAP
- Initiated Nivolumab between May 2015 and August 2017
- Attending clinician agreeable to provide patient data
- Local institutional ethics requirements satisfied
- Exclusion Criteria:
- Insufficient data available
- Other protocol defined inclusion/exclusion criteria could apply
Exclusion
Key Trial Info
Start Date :
October 3 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 12 2021
Estimated Enrollment :
503 Patients enrolled
Trial Details
Trial ID
NCT03804554
Start Date
October 3 2018
End Date
August 12 2021
Last Update
May 27 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Heidelburg, Victoria, Australia, 3084